Çocuk ve Ergenlerde Antidepresan Tedavi
Özet
Çocuk ve ergenlerde antidepresan tedavi, kanıta dayalı veriler ışığında Majör Depresif Bozukluk, Anksiyete Bozuklukları ve OKB gibi çeşitli psikiyatrik rahatsızlıkların tedavisinde giderek yaygınlaşmaktadır. Bu yaş grubundaki farmakodinamik ve farmakokinetik farklılıklar nedeniyle kiloya göre dozlama yapılması ve karaciğer ile böbrek atılım kapasitelerinin göz önünde bulundurulması kritik önem taşır. Doğru tanı koymak amacıyla ebeveyn ve çocukla kapsamlı görüşmeler yapılması, gereksiz ilaç kullanımını önlemek için şarttır. Tedaviye uyumu olumsuz etkileyen ailevi ön yargılar, yan etkiler ve sosyoekonomik faktörler süreçte dikkatle yönetilmelidir. İlaç kullanımı öncesinde hasta ve ebeveynlerden aydınlatılmış yazılı onam alınması etik bir zorunluluktur. Güvenilirlikleri ve geniş spektrumları nedeniyle Seçici Serotonin Geri Alım İnhibitörleri (SSGİ) birinci basamak tedavi ajanı olarak kabul edilir. Fluoksetin, MDB ve OKB için FDA onayı almış en güçlü kanıta sahip antidepresandır. Sertralin ve fluvoksamin OKB tedavisinde öne çıkarken, duloksetin yaygın anksiyete bozukluğu için onaylı tek ajandır. Atipik antidepresanlar ve kardiyak riskleri nedeniyle kısıtlı kullanılan trisiklik antidepresanlar ise dirençli vakalarda tercih edilen diğer seçeneklerdir. Sonuç olarak, çocuk ve ergenlerde tedavi süreci, uzman hekim tarafından yakın takip ve ebeveyn iş birliğiyle kâr-zarar dengesi gözetilerek titizlikle yürütülmelidir.
Antidepressant treatment in children and adolescents is becoming increasingly widespread in light of evidence-based data for treating various psychiatric disorders such as Major Depressive Disorder, Anxiety Disorders, and OCD. Due to pharmacodynamic and pharmacokinetic differences in this age group, weight-based dosing and taking renal and hepatic excretion capacities into account carry critical importance. Conducting comprehensive diagnostic interviews with both parents and children is essential to prevent unnecessary medication use. Socioeconomic factors, side effects, and familial prejudices that negatively impact treatment adherence must be managed carefully throughout the process. Obtaining informed written consent from patients and parents prior to drug initiation is an ethical necessity. Selective Serotonin Reuptake Inhibitors (SSRIs) are accepted as first-line therapeutic agents due to their safety profiles and broad spectrum of efficacy. Fluoxetine is the antidepressant with the strongest level of evidence, holding FDA approval for MDD and OCD. While sertraline and fluvoxamine stand out in OCD treatment, duloxetine is the only approved agent for generalized anxiety disorder. Atypical antidepressants and tricyclic antidepressants, which are limited due to cardiac risks, represent other choices preferred in treatment-resistant cases. In conclusion, the treatment process in children and adolescents must be meticulously conducted by an expert clinician through close monitoring and parental cooperation, carefully weighing the benefit-risk ratio.
Referanslar
ALŞEN GÜNEY S, ŞAHBUDAK B. Çocuk ve Ergen Psikiyatrisinde Antidepresanlar ve Anksiyolitikler. Turkiye Klinikleri J Child Psychiatry-Special Topics. 2017;3(1):8-15.
Kütük MÖ, Karakoç Demirkaya S. Çocuk ve Ergenlerde Psikotropik İlaç Kullanımı Farklılıkları ve Genel İlkeleri. Turkiye Klinikleri J Child Psychiatry-Special Topics. 2017;3(1):1-7.
Koelch M, Schnoor K, Fegert JM. Ethical issues in psychopharmacology of children and adolescents. Curr Opin Psychiatry. 2008;21(6):598-605. doi:10.1097/YCO.0b013e328314b776
Erdoğan N, Kara M, Hızal A, Hızal S. Aydınlatılmış onam uygulama ve tıp hukuku açısından sorunlar. Erciyes Tıp Dergisi 2011;33(2): 165-70
Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Pharmacotherapy in depressed children and adolescents. World J Biol Psychiatry. 2011;12 Suppl 1:11-15. doi:10.3109/15622975.2011.600295
Xuev S, Ickowicz A. Serotonin Syndrome in Children and Adolescents Exposed to Selective Serotonin Reuptake Inhibitors - A Review of Literature. J Can Acad Child Adolesc Psychiatry. 2021;30(3):156-164.
Li K, Zhou G, Xiao Y, et al. Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies. Front Psychiatry. 2022;13:880496. Published 2022 May 26. doi:10.3389/fpsyt.2022.880496
Unguru Y, Sill AM, Kamani N. The experiences of children enrolled in pediatric oncology research: implications for assent. Pediatrics. 2010;125(4):e876-e883. doi:10.1542/peds.2008-3429
Sadock J & Kaplan B (2016), Kaplan & Sadock Psikiyatri (Ali BOZKURT, Çev. Ed.). Ankara: Güneş Tıp Kitabevi.
Sohel AJ, Shutter MC, Molla M. Fluoxetine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 4, 2022.
Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11-28. doi:10.1016/s0163-7258(99)00048-0
Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54(11):1031-1037. doi:10.1001/archpsyc.1997.01830230069010
Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1205-1215. doi:10.1097/00004583-200210000-00010
March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-820. doi:10.1001/jama.292.7.807
Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45(12):1404-1411. doi:10.1097/01.chi.0000242228.75516.21
Capitão LP, Chapman R, Murphy SE, et al. A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents. Transl Psychiatry. 2019;9(1):30. Published 2019 Jan 21. doi:10.1038/s41398-018-0332-2
Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-1696. doi:10.1001/jama.297.15.1683
Black B, Uhde TW. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1994;33(7):1000-1006. doi:10.1097/00004583-199409000-00010
Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415-423. doi:10.1097/01.CHI.0000037049.04952.9F
Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1622-1632. doi:10.1097/chi.0b013e318154bb57
Kotler LA, Devlin MJ, Davies M, Walsh BT. An open trial of fluoxetine for adolescents with bulimia nervosa. J Child Adolesc Psychopharmacol. 2003;13(3):329-335. doi:10.1089/104454603322572660
Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30(3):582-589. doi:10.1038/sj.npp.1300627
Semerci, B., Öztürk, M., (2015), Depresif Bozukluk. Tümer Türkbay (Ed.), Çocuk ve Ergen Psikofarmokolojisi (110). İstanbul: PEDAM
Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001;40(7):773-779. doi:10.1097/00004583-200107000-00011
Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002;41(12):1431-1438. doi:10.1097/00004583-200212000-00014
Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1992;31(6):1062-1069. doi:10.1097/00004583-199211000-00011
DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clinical Pharmacokinetics. 2002;41(15):1247-1266. doi:10.2165/00003088-200241150-00002
Wagner KD. Pharmacotherapy for major depression in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):819-826. doi:10.1016/j.pnpbp.2005.03.005
Semerci, B., Öztürk, M., (2015), Depresif Bozukluk. Tümer Türkbay (Ed.), Çocuk ve Ergen Psikofarmokolojisi (138). İstanbul: PEDAM
Garcia AM, Sapyta JJ, Moore PS, et al. Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). J Am Acad Child Adolesc Psychiatry. 2010;49(10):1024-1086. doi:10.1016/j.jaac.2010.06.013
Storch EA, Bussing R, Small BJ, et al. Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther. 2013;51(12):823-829. doi:10.1016/j.brat.2013.09.007
Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety [published correction appears in N Engl J Med. 2013 Jan 31;368(5):490]. N Engl J Med. 2008;359(26):2753-2766. doi:10.1056/NEJMoa0804633
Walter HJ, Bukstein OG, Abright AR, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005
Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC STEERING GROUP. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. Pediatrics. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082
Mukaddes NM, Abali O, Kaynak N. Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci. 2003;57(4):405-408. doi:10.1046/j.1440-1819.2003.01139.x
Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001;11(4):275-283. doi:10.1016/s0924-977x(01)00101-8
Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161(6):1079-1083. doi:10.1176/appi.ajp.161.6.1079
von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006;26(3):311-315. doi:10.1097/01.jcp.0000219051.40632.d5
Sharp SC, Hellings JA. Efficacy and safety of selective serotonin reuptake inhibitors in the treatment of depression in children and adolescents: practitioner review. Clin Drug Investig. 2006;26(5):247-255. doi:10.2165/00044011-200626050-00002
Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-290. doi:10.2165/00003088-200746040-00002
Periclou A, Rao N, Sherman T, et al. Single-dose pharmacokinetic study of escitalopram in adolescents and adults [abstract]. Pharmacotherapy 2003; 23(10): 1361–2
Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):280-288. doi:10.1097/01.chi.0000192250.38400.9e
Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety [published correction appears in N Engl J Med. 2013 Jan 31;368(5):490]. N Engl J Med. 2008;359(26):2753-2766. doi:10.1056/NEJMoa0804633
Findling RL, Robb A, Bose A. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. J Child Adolesc Psychopharmacol. 2013;23(7):468-480. doi:10.1089/cap.2012.0023
Lu L, Mills JA, Li H, et al. Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2021;60(10):1309-1318. doi:10.1016/j.jaac.2020.11.023
Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 2001;7(1):25-47. doi:10.1111/j.1527-3458.2001.tb00189.x
Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006;45(6):709-719. doi:10.1097/01.chi.0000214189.73240.63
Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006;16(1-2):59-75. doi:10.1089/cap.2006.16.59
Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40(7):762-772. doi:10.1097/00004583-200107000-00010
Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004;43(11):1387-1396. doi:10.1097/01.chi.0000138356.29099.f1
Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61(11):1153-1162. doi:10.1001/archpsyc.61.11.1153
Figgitt DP, McClellan KJ. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs. 2000;60(4):925-954. doi:10.2165/00003495-200060040-00006
Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):222-229. doi:10.1097/00004583-200102000-00017
Apter A, Ratzoni G, King RA, et al. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry. 1994;33(3):342-348. doi:10.1097/00004583-199403000-00007
Macher E, Macciotta B, Castro MJ. 11th World Psychiatry Congress. In: Fluvoxamine in Adolescents with Obsessive-Compulsive Disorder [Summary]. . Vol 108. Geneva: World Psychiatric Association; 1999.
Walkup JT, Labellarte MJ, Riddle MA, et al. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine. 2001;344(17):1279-1285. doi:10.1056/nejm200104263441703
Cheer SM, Figgitt DP. Spotlight on fluvoxamine in anxiety disorders in children and adolescents. CNS Drugs. 2002;16(2):139-144. doi:10.2165/00023210-200216020-00006
Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull. 1997;33(1):149-154.
Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y, Dum BL. Efficacy and safety of venlafaxine extended release in children and adolescents with MDD. 157th Annual Meeting of the American Psychiatric Association. New York, N.Y., 2004
Emslie GJ, Mayes T, Porta G, et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry. 2010;167(7):782-791. doi:10.1176/appi.ajp.2010.09040552
March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007;62(10):1149-1154. doi:10.1016/j.biopsych.2007.02.025
Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry. 2007;164(2):290-300. doi:10.1176/ajp.2007.164.2.290
Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40(3):307-314. doi:10.1097/00004583-200103000-00010
Ng QX. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. J Child Adolesc Psychopharmacol. 2017;27(2):112-116. doi:10.1089/cap.2016.0124
Jafarinia M, Mohammadi MR, Modabbernia A, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol. 2012;27(4):411-418. doi:10.1002/hup.2242
Muramoto ML, Leischow SJ, Sherrill D, Matthews E, Strayer LJ. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med. 2007;161(11):1068-1074. doi:10.1001/archpedi.161.11.1068
Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine. Clinical Pharmacokinetics. 2011;50(5):281-294. doi:10.2165/11539240-000000000-00000
Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27. Published 2019 May 28. doi:10.1186/s12969-019-0325-6
Strawn JR, Prakash A, Zhang Q, et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(4):283-293. doi:10.1016/j.jaac.2015.01.008
Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057-1070. doi:10.1080/14656566.2018.1491966
Atkinson SD, Prakash A, Zhang Q, et al. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014;24(4):180-189. doi:10.1089/cap.2013.0146
Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249-264. doi:10.1111/j.1527-3458.2001.tb00198.x
Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005;46(7):735-754. doi:10.1111/j.1469-7610.2005.01467.x
Coskun M, Alyanak B. Psychiatric Co-morbidity and Efficacy of Mirtazapine Treatment in Young Subjects With Chronic or Cyclic Vomiting Syndromes: A Case Series. J Neurogastroenterol Motil. 2011;17(3):305-311. doi:10.5056/jnm.2011.17.3.305
Maneeton N, Srisurapanont M. Tricyclic antidepressants for depressive disorders in children and adolescents: a meta-analysis of randomized-controlled trials. J Med Assoc Thai. 2000;83(11):1367-1374.
DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial. J Am Acad Child Adolesc Psychiatry. 1992;31(1):45-49. doi:10.1097/00004583-199201000-00008
Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2014;(9):CD006997. Published 2014 Sep 19. doi:10.1002/14651858.CD006997.pub2
